Previous Close | 0.6100 |
Open | 0.5902 |
Bid | 0.5401 x 1100 |
Ask | 0.5774 x 900 |
Day's Range | 0.5700 - 0.6900 |
52 Week Range | 0.3550 - 1.3500 |
Volume | |
Avg. Volume | 76,213 |
Market Cap | 24.664M |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2200 |
Earnings Date | Apr 19, 2024 - Apr 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Feb 27, 2023 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for QLI
Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
Qilian International Holding Group ( NASDAQ:QLI ) First Half 2023 Results Key Financial Results Revenue: US$29.2m (down...
Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), dated July 13, 2023, that the Company is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on The Nasdaq Global Market (the "Nasdaq Global Market"). The Notification Letter is only a notifica